Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Isopropyl Myristate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.79 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | PRKCA | P17252 | 4/20 | 0.55 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.55 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.55 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | DGKA | P23743 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isopropyl Myristate SCHEMBL8908510 | 0.98 | LMNA (0.82) | LMNAMAPTMAPK1PRKCAPRKCE | |
| Isopropyl Palmitate SCHEMBL27946744 | 0.98 | LMNA (0.82) | LMNAMAPTMAPK1PRKCAPRKCE | |
| Isopropyl Palmitate SCHEMBL4154364 | 0.93 | LMNA (0.92) | LMNAMAPTMAPK1PRKCAPRKCE | |
| Isopropyl Myristate SCHEMBL1821126 | 0.93 | LMNA (0.92) | LMNAMAPTMAPK1PRKCAPRKCE | |
| Isopropyl Palmitate SCHEMBL28114565 | 0.92 | LMNA (0.68) | LMNAMAPTMAPK1PRKCAPRKCE | |
| Isopropyl Myristate SCHEMBL5157367 | 0.90 | LMNA (0.79) | LMNAMAPTMAPK1PRKCAPRKCE | |
| Isopropyl Palmitate SCHEMBL7802437 | 0.90 | LMNA (0.79) | LMNAMAPTMAPK1PRKCAPRKCE | |
| Isopropyl Myristate SCHEMBL8908680 | 0.89 | MAPT (0.77) | LMNAMAPTMAPK1PRKCAPRKCE | |
| Isopropyl Alcohol SCHEMBL1163664 | 0.89 | LMNA (0.92) | LMNAMAPTMAPK1PRKCAPRKCE | |
| Isopropyl Myristate SCHEMBL3022720 | 0.89 | LMNA (0.92) | LMNAMAPTMAPK1PRKCAPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4050002-A1 | ANTI-PROLIFERATIVE AGENTS | First Health Pharmaceuticals B.V. (NL) | 2022-08-31 | — | — | EP | disclosed |
| US-11000512-B2 | Use of DDX3 inhibitors as antiproliferative agents | AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) | 2021-05-11 | — | — | US | disclosed |
| US-8183222-B2 | Method to inhibit cell growth using oligonucleotides | TRUSTEES OF BOSTON UNIVERSITY (US) | 2012-05-22 | — | — | US | disclosed |
| EP-2363133-A1 | Composition comprising DNA fragments and medical and cosmetic uses thereof | Trustees of Boston University (US) | 2011-09-07 | — | — | EP | disclosed |
| US-20100222419-A1 | METHOD TO INHIBIT CELL GROWTH USING OLIGONUCLEOTIDES | TRUSTEES OF BOSTON UNIVERSITY (US) | 2010-09-02 | — | — | US | disclosed |
| EP-2210956-A2 | Method to inhibit cell growth using oligonucleotides | Trustees of Boston University (US) | 2010-07-28 | — | — | EP | disclosed |
| EP-1582210-B1 | Use of an antimicrotubule agent for treating or preventing surgical adhesions | ANGIOTECH INT AG (CH) | 2010-02-10 | — | — | EP | disclosed |
| US-20090209747-A1 | METHOD TO INHIBIT CELL GROWTH USING OLIGONUCLEOTIDES | TRUSTEES OF BOSTON UNIVERSITY (US) | 2009-08-20 | — | — | US | disclosed |
| US-20080153900-A1 | Compositions and methods for treating or preventing imflammatory diseases | ANGIOTECH INTERNATIONAL AG (CH) | 2008-06-26 | — | — | US | disclosed |
| US-20080113035-A1 | Compositions and methods for treating or preventing inflammatory diseases | ANGIOTECH INTERNATIONAL AG (CH) | 2008-05-15 | — | — | US | disclosed |
| EP-1090637-A2 | Compositions and methods for treating or preventing inflammatory diseases | Angiotech Pharmaceuticals, Inc. (CA) | 2001-04-11 | — | — | EP | disclosed |
| EP-1070502-A2 | Compositions and methods for treating or preventing inflammatory diseases | Angiotech Pharmaceuticals, Inc. (CA) | 2001-01-24 | — | — | EP | disclosed |
| US-6147056-A | THERAPY FOR PSORIASIS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2000-11-14 | — | — | US | disclosed |
| CN-1246791-A | Compositions and methods for treating or preventing inflammatory diseases | ANGIOTECH PHARM INC (CA) | 2000-03-08 | — | — | CN | disclosed |
| WO-1999062510-A2 | COMPOSITIONS COMPRISING ANTI-MICROTUBULE AGENTS FOR TREATING OR PREVENTING INFLAMMATORY DISEASES | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 1999-12-09 | — | — | WO | disclosed |
| US-5955059-A | TREATING PSORIASIS, OTHER SKIN DISORDERS | TRUSTEES OF BOSTON UNIVERSITY (US) | 1999-09-21 | — | — | US | disclosed |
| EP-0941089-A2 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING INFLAMMATORY DISEASES | Angiotech Pharmaceuticals, Inc. (CA) | 1999-09-15 | — | — | EP | disclosed |
| WO-1998024427-A2 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING INFLAMMATORY DISEASES | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 1998-06-11 | — | — | WO | disclosed |
| EP-0831850-A1 | USE OF LOCALLY APPLIED DNA FRAGMENTS | TRUSTEES OF BOSTON UNIVERSITY (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996039152-A1 | USE OF LOCALLY APPLIED DNA FRAGMENTS | TRUSTEES OF BOSTON UNIVERSITY (US) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11000512-B2 | Use of DDX3 inhibitors as antiproliferative agents | DDX3X, DDX21, DDB1 | LMNA 2369/4885MAPT 4194/4885MAPK1 1608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.